Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Solis Women’s Health names new chief medical officer
Dr Lander replaces Timothy Freer, the founder of Solis’s predecessor organization, and the first chief medical officer of Solis, who has retired. Dr Lander is the lead physician
Dr Lander replaces Timothy Freer, the founder of Solis’s predecessor organization, and the first chief medical officer of Solis, who has retired. Dr Lander is the lead physician
In this role, Mr Flounlacker will be responsible for coordinating operations across the company among other senior executives to optimize company resources to achieve training targets, sales and
In this role, Mr Kelley will be responsible for the company’s direct subsidiaries in four European countries, Japan, China and Korea, and for Cynosure distributors covering an additional
Ms Zimmerman, a certified public accountant and a member of the American Institute of Certified Public Accountants, brings more than 30 years of responsible financial oversight to her
Existing investors, Polaris Venture Partners and Flagship Ventures were joined by NanoDimension and professor Timothy Springer. The proceeds of this financing will be used to expand Selecta’s R&D
Synexus through its network of wholly owned sites staffed by full time good clinical practice trained investigators is able to carry out the whole of a Phase II
The marketing application submitted to the Australian regulatory authorities included safety and efficacy data from three multi-national clinical studies: Triumph, a placebo-controlled 26-week Phase III study involving 87
Dr Scarlett brings nearly 30 years of experience in drug development and commercialization to his new role. Susan Molineaux, who founded Proteolix in 2003, will transition from her
As part of the agreement, Sigma-Tau will make a $6 million upfront investment in Dor, inclusive of the $1.5 million which was recently completed under a letter of
The program consists of three randomized, double-blind, placebo-controlled Phase III clinical studies with Cerimon’s diclofenac patch. The studies will assess the efficacy and safety of Cerimon’s diclofenac patch